Maravai LifeSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Updates 2022 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Maravai LifeScience Holdings Inc. (MRVI) PT Lowered to $45 at Stifel
February 24, 2022 7:14 AM ESTStifel analyst Daniel Arias lowered the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $45.00 (from $56.00) while maintaining a Buy rating.
The analyst commented, "MRVI posted a solid top- and bottom-line beat driven by strength in CleanCap. Along with earnings, management provided... More
Maravai LifeSciences (MRVI) Tops Q4 EPS by 7c; Guides Higher
February 23, 2022 4:57 PM ESTMaravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of $0.45, $0.07 better than the analyst estimate of $0.38. Revenue for the quarter came in at $228.4 million versus the consensus estimate of $208.09 million.
GUIDANCE:
Maravai LifeSciences sees FY2022 EPS of $1.70-$1.84, versus the consensus of $1.54.... More
